ERRATUM

Hyperglycemia decreases anti-cancer efficiency of adriamycin via AMPK pathway

Xiaqing Xu^{1,*}, Meimei Si^{1,*}, Honggang Lou², Youyou Yan¹, Yunxi Liu¹, Hong Zhu¹, Xiaoe Lou¹, Jian Ma¹, Difeng Zhu¹, Honghai Wu¹, Bo Yanz¹, Haoshu Wu¹, Ling Ding¹ and Qiaojun He¹

¹Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology & Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

²Department of Clinical Pharmacology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Correspondence should be addressed to L Ding or Q He: ld362@zju.edu.cn or qiaojunhe@zju.edu.cn

*(X Xu and M Si contributed equally to this work)

Endocrine-Related Cancer
(2020) **27**, X3–X4

The authors and journal apologise for an error in the above paper, which appeared in volume 25 part 11, pages 955–966. The error relates to the artwork of Fig. 5 on page 963, in which the blots given in panel E were mistakenly replicated in panel F.

The correct [Fig. 5](#) is given in full below:

Figure 5

High glucose decreases the cytotoxicity of ADR by downregulating AMPK pathway. (A and B) HepG2 and Bel-7402 cells were pretreated with 5 μ M compound C for 2 h. (C and D) HepG2 and Bel-7402 cells were transfected with siRNAs specifically targeting AMPK or control siRNAs. (E and F) HepG2 and Bel-7402 cells were pretreated with 0.5 mM AICAR for 2 h. Then, cells were exposed to ADR as indicated in different glucose conditions for 48 h. Cell-proliferation inhibitory activities were determined by SRB assay. Protein expressions were detected by Western blot analysis.